Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Translational oncology: Tumour mutational burden and exploitation of DNA repair

Written by | 5 Jul 2019

Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.

EHA 2019: CASSIOPEIA study

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Among the clinical studies that reported results at the EHA congress 2019 was part 1 of the CASSIOPEIA study…. read more.

EHA 2019: COLUMBA study

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.

EHA 2019: Late-breaking abstracts at EHA

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Oral selective BCL-2 inhibitor venetoclax has demonstrated encouraging clinical efficacy against MM. As monotherapy, venetoclax has shown to be… read more.

Advances in RRMM

Written by | 9 May 2019

Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study

Transplantation, Consolidation and Maintenance

Written by | 8 May 2019

  Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.

Integrating CAR T-Cell therapy into the treatment of myeloma

Written by | 7 May 2019

Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.

State of the art clinical trials

Written by | 6 May 2019

Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).

Bridging the gap between clinical trial results and real-world myeloma practices

Written by | 5 May 2019

Professor Graham Jackson (Newcastle, UK) gives an overview of his presentation  on real world management of myeloma patients in the UK, with comments from Professor Sagar Lonial (Atlanta, USA). Professor Jackson… read more.

Maintenance therapy in newly diagnosed MM – a reality in the UK?

Written by | 4 May 2019

Professor Gordon Cook (Leeds, UK), Professor Guy Pratt (Birmingham, UK) and Professor Graham Jackson (Newcastle, UK) discuss the need for maintenance in the up-front setting for UK patients and the new data on… read more.

What are the opportunities for genomic-driven change in lymphoma?

Written by | 3 May 2019

Dr Chris Fox (Nottingham, UK) highlights another presentation from Lymphoma SIG around the opportunities for genomic-driven change in lymphoma.

Frontline therapy in multiple myeloma therapy: current evidence and future research

Written by | 2 May 2019

Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.